Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25405070 | 1.00 | GPR119 (0.46) | GPR119JAK2JAK3PTK2CYP11B1 | |
| SCHEMBL23980945 | 0.89 | GPR119 (0.45) | GPR119NAMPTUTS2RSTS | |
| SCHEMBL25403420 | 0.88 | MEN1 (0.43) | NAMPTUTS2RSTS | |
| SCHEMBL27288015 | 0.88 | MEN1 (0.43) | NAMPTUTS2RSTS | |
| SCHEMBL23980870 | 0.88 | MEN1 (0.43) | NAMPTUTS2RSTS | |
| SCHEMBL25404424 | 0.86 | CYP11B1 (0.43) | CYP11B1CYP11B2DRD2HTR2ADRD3 | |
| SCHEMBL25404417 | 0.86 | CYP11B1 (0.43) | CYP11B1CYP11B2DRD2HTR2ADRD3 | |
| SCHEMBL31159904 | 0.81 | GPR119 (0.50) | GPR119JAK2JAK3PTK2DRD2 | |
| SCHEMBL31159865 | 0.81 | GPR119 (0.50) | GPR119JAK2JAK3PTK2DRD2 | |
| SCHEMBL31159851 | 0.81 | GPR119 (0.50) | GPR119JAK2JAK3PTK2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552791-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4143183-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250214999-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2025-07-03 | — | — | US | disclosed |
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2021219019-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | GPR119 11/4885JAK2 787/4885JAK3 1325/4885 |
| US-12552791-B2 | Heterocyclic GLP-1 agonists | GLP1R, NPY1R, NPY2R | GPR119 24/4885JAK2 1305/4885JAK3 2423/4885 |
| US-20250214999-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | GPR119 11/4885JAK2 787/4885JAK3 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.